PI3K pathway alterations in cancer: variations on a theme (original) (raw)
Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N et al. (2008). Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene27: 3539–3545. CASPubMed Google Scholar
Arteaga CL . (2006). EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell9: 421–423. CASPubMed Google Scholar
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther3: 772–775. CASPubMed Google Scholar
Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM et al. (2008). Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer122: 2255–2259. CASPubMed Google Scholar
Barnes KR, Blois J, Smith A, Yuan H, Reynolds F, Weissleder R et al. (2008). Fate of a bioactive fluorescent wortmannin derivative in cells. Bioconjug Chem19: 130–137. CASPubMed Google Scholar
Bauer S, Duensing A, Demetri GD, Fletcher JA . (2007). KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene26: 7560–7568. CASPubMed Google Scholar
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell12: 395–402. CASPubMed Google Scholar
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD et al. (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther5: 2676–2684. CASPubMed Google Scholar
Cantley LC . (2002). The phosphoinositide 3-kinase pathway. Science296: 1655–1657. CASPubMed Google Scholar
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature448: 439–444. CASPubMed Google Scholar
Chen JS, Zhou LJ, Entin-Meer M, Yang X, Donker M, Knight ZA et al. (2008). Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther7: 841–850. CASPubMed Google Scholar
Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature436: 725–730. CASPubMedPubMed Central Google Scholar
Crabbe T, Welham MJ, Ward SG . (2007). The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci32: 450–456. CASPubMed Google Scholar
Downward J . (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer3: 11–22. CASPubMed Google Scholar
Engelman JA . (2007). The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res13: s4637–s4640. PubMed Google Scholar
Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA102: 3788–3793. CASPubMedPubMed Central Google Scholar
Engelman JA, Luo J, Cantley LC . (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet7: 606–619. CASPubMed Google Scholar
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316: 1039–1043. CASPubMed Google Scholar
Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM et al. (2007). A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res67: 7960–7965. CASPubMedPubMed Central Google Scholar
Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. (2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell9: 341–349. ArticleCASPubMedPubMed Central Google Scholar
Folkman J . (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov6: 273–286. CASPubMed Google Scholar
Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K et al. (2006). PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer94: 247–252. CASPubMedPubMed Central Google Scholar
Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, Yoshida-Araki K et al. (2004). Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem279: 34741–34749. CASPubMed Google Scholar
Garlich JR, De P, Dey N, Su JD, Peng X, Miller A et al. (2008). A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res68: 206–215. CASPubMed Google Scholar
Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et al. (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature453: 662–666. CASPubMed Google Scholar
Gupta GP, Massague J . (2006). Cancer metastasis: building a framework. Cell127: 679–695. CASPubMed Google Scholar
Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell129: 957–968. CASPubMed Google Scholar
Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J et al. (2005). The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev19: 2054–2065. CASPubMedPubMed Central Google Scholar
Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins. J Cell Biol166: 213–223. CASPubMedPubMed Central Google Scholar
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science299: 708–710. CASPubMed Google Scholar
Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D . (2003). Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res63: 1130–1137. CASPubMed Google Scholar
Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T et al. (2005). HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res65: 4253–4260. CASPubMed Google Scholar
Hirsch E, Ciraolo E, Ghigo A, Costa C . (2008). Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther118: 192–205. CASPubMed Google Scholar
Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. (2000). Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science287: 1049–1053. CASPubMed Google Scholar
Hofer E, Schweighofer B . (2007). Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost97: 355–363. CASPubMedPubMed Central Google Scholar
Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M . (2007). Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res5: 195–201. CASPubMed Google Scholar
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K et al. (2007). The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther6: 2505–2514. CASPubMed Google Scholar
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW et al. (2007). The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science318: 1744–1748. CASPubMed Google Scholar
Ikeda T, Yoshinaga K, Suzuki A, Sakurada A, Ohmori H, Horii A . (2000). Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep7: 567–570. CASPubMed Google Scholar
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res65: 10992–11000. CASPubMed Google Scholar
Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS et al. (2008). PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res68: 1953–1961. CASPubMedPubMed Central Google Scholar
Kang S, Seo SS, Chang HJ, Yoo CW, Park SY, Dong SM . (2008). Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer; e-pub ahead of print.
Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M et al. (2007). PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer121: 1771–1778. CASPubMed Google Scholar
Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T . (2007). Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol27: 662–677. CASPubMed Google Scholar
Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell125: 733–747. CASPubMedPubMed Central Google Scholar
Kolsch V, Charest PG, Firtel RA . (2008). The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci121: 551–559. CASPubMed Google Scholar
Kong D, Yamori T . (2007). ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci98: 1638–1642. CASPubMed Google Scholar
Koyasu S . (2003). The role of PI3K in immune cells. Nat Immunol4: 313–319. CASPubMed Google Scholar
Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K et al. (2007). Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell12: 81–93. CASPubMed Google Scholar
Lim KH, Counter CM . (2005). Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell8: 381–392. CASPubMed Google Scholar
Martin-Belmonte F, Mostov K . (2008). Regulation of cell polarity during epithelial morphogenesis. Curr Opin Cell Biol20: 227–234. CASPubMed Google Scholar
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med353: 2012–2024. CASPubMed Google Scholar
Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science317: 239–242. CASPubMed Google Scholar
Moasser MM . (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene26: 6469–6487. CASPubMedPubMed Central Google Scholar
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6: 117–127. CASPubMed Google Scholar
Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK . (2002). Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res62: 6764–6769. CASPubMed Google Scholar
Oda K, Stokoe D, Taketani Y, McCormick F . (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res65: 10669–10673. CASPubMed Google Scholar
Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R et al. (2007). Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer121: 915–920. CASPubMed Google Scholar
Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE et al. (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res13: 3577–3584. CASPubMed Google Scholar
Ramjaun AR, Downward J . (2007). Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle6: 2902–2905. CASPubMed Google Scholar
Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature370: 527–532. CASPubMed Google Scholar
Rommel C, Camps M, Ji H . (2007). PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol7: 191–201. CASPubMed Google Scholar
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res65: 2554–2559. CASPubMed Google Scholar
Salmena L, Carracedo A, Pandolfi PP . (2008). Tenets of PTEN tumor suppression. Cell133: 403–414. CASPubMed Google Scholar
Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell7: 561–573. CASPubMed Google Scholar
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science304: 554. CASPubMed Google Scholar
Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA . (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol9: 493–505. CASPubMed Google Scholar
Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG . (1996). Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol148: 1047–1053. CASPubMedPubMed Central Google Scholar
Soltoff SP, Carraway III KL, Prigent SA, Gullick WG, Cantley LC . (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol14: 3550–3558. CASPubMedPubMed Central Google Scholar
Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature431: 525–526. CASPubMed Google Scholar
Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science318: 287–290. CASPubMed Google Scholar
Suire S, Hawkins P, Stephens L . (2002). Activation of phosphoinositide 3-kinase gamma by Ras. Curr Biol12: 1068–1075. CASPubMed Google Scholar
Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D et al. (2005). Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA102: 128–133. CASPubMed Google Scholar
Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K et al. (2007). Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat101: 249–257. CASPubMed Google Scholar
Tornillo L, Terracciano LM . (2006). An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol59: 557–563. CASPubMedPubMed Central Google Scholar
Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz Jr S et al. (2005). The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer41: 1649–1654. CASPubMed Google Scholar
Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell6: 909–919. CASPubMed Google Scholar
Walker EH, Perisic O, Ried C, Stephens L, Williams RL . (1999). Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature402: 313–320. CASPubMed Google Scholar
Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM et al. (2006). Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res66: 7864–7869. CASPubMed Google Scholar
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res64: 7099–7109. CASPubMed Google Scholar
Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD et al. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol16: 1722–1733. CASPubMedPubMed Central Google Scholar
Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H et al. (2006). Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst98: 545–556. CASPubMed Google Scholar
Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L . (2007). Covalent reactions of wortmannin under physiological conditions. Chem Biol14: 321–328. CASPubMed Google Scholar
Zhao L, Vogt PK . (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA105: 2652–2657. CASPubMedPubMed Central Google Scholar